Location of Repository

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome

By Ruchi Mathur, Olga Levin and Ricardo Azziz

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2504056
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1965). [In vivo studies on metabolism of androgens following administration of steroid inhibitors of ovulation. 1. Changes in the secretion of androgens and excretion of their metabolites in normal subjects and women with the Stein-Leventhal syndrome].
    2. (1999). A prospective randomized trial comparing low dose fl utamide, fi nasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism.
    3. (2006). A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 mcg ethinyl estradiol and a reference containing desogestrel and 30 mcg ethinyl estradiol.
    4. (2004). An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care,
    5. (2002). Androgen and lipid profi les in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril,
    6. (2006). Androgen excess disorders in women, polycystic ovary syndrome and other disorders. 2nd ed.
    7. (1993). Androgens in polycystic ovarian syndrome.
    8. (2006). Choice of treatment for women with polycystic ovary syndrome. Fertil Steril, 86(Suppl 1):S22–3.
    9. (2002). Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod,
    10. (2000). Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profi le.
    11. (2005). Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update,
    12. (2000). Comparison of spironolactone, fl utamide, and fi nasteride effi cacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.
    13. (1991). Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clinic Endocrinol(Oxf),
    14. (2002). Diurnal rhythm of and effects on oral contraceptives on serum dehydroepiandrosterone sulphate (DHEAS) are related to alterations in serum albumin rather than to changes in adrenocortical steroid secretion.
    15. (2004). Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.
    16. (2003). Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.
    17. (1995). Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand,
    18. (1990). Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone.
    19. (1998). Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome.
    20. (2006). Effi cacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    21. (2007). Effi cacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care,
    22. (2000). Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    23. (2007). Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril,
    24. (1998). Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.
    25. (2001). Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
    26. (2002). Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod,
    27. (1995). Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.
    28. (2003). Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    29. (2002). New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv,
    30. (1999). Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol,
    31. (2007). Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod,
    32. (1998). Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.
    33. (1997). The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
    34. (2005). The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod,
    35. (2004). The prevalence and features of the polycystic ovary syndrome in an unselected population.
    36. (2007). The safety of a drospirenone containing oral contraceptive: fi nal results from the European Active Surveillance study on oral contraceptives based on 142,475 women – years of observation.
    37. (2000). Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has benefi cial effects on the lipid profi le and improves insulin sensitivity. Fertil Steril,
    38. (1975). Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.